@prefix : <http://semanticscholar.org/cv-research/> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix fhir_link: <http://hl7.org/fhir/link/> .
@prefix ncit: <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sso: <http://semanticscholar.org/cv-research/> .
@prefix whocv: <http://semanticscholar.org/cv-research/WHO#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<http://fhircat.org/cord-19/metadata/5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7> fhir_link: <https://fhircat.org/cord-19/fhir/Commercial/5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7> ;
    dc:abstract "BACKGROUND: The prevalence of pneumocystis pneumonia (PCP) and associated hypoxic respiratory failure is increasing in human immunodeficiency virus (HIV)-negative patients. However, no prior studies have evaluated the effect of early anti-PCP treatment on clinical outcomes in HIV-negative patient with severe PCP. Therefore, this study investigated the association between the time to anti-PCP treatment and the clinical outcomes in HIV-negative patients with PCP who presented with hypoxemic respiratory failure. METHODS: A retrospective observational study was performed involving 51 HIV-negative patients with PCP who presented in respiratory failure and were admitted to the intensive care unit between October 2005 and July 2018. A logistic regression model was used to adjust for potential confounding factors in the association between the time to anti-PCP treatment and in-hospital mortality. RESULTS: All patients were treated with appropriate anti-PCP treatment, primarily involving trimethoprim/sulfamethoxazole. The median time to anti-PCP treatment was 58.0 (28.0–97.8) hours. Thirty-one (60.8%) patients were treated empirically prior to confirmation of the microbiological diagnosis. However, the hospital mortality rates were not associated with increasing quartiles of time until anti-PCP treatment (P = 0.818, test for trend). In addition, hospital mortality of patients received early empiric treatment was not better than those of patients received definitive treatment after microbiologic diagnosis (48.4% vs. 40.0%, P = 0.765). In a multiple logistic regression model, the time to anti-PCP treatment was not associated with increased mortality. However, age (adjusted OR 1.07, 95% CI 1.01–1.14) and failure to initial treatment (adjusted OR 13.03, 95% CI 2.34–72.65) were independently associated with increased mortality. CONCLUSIONS: There was no association between the time to anti-PCP treatment and treatment outcomes in HIV-negative patients with PCP who presented in hypoxemic respiratory failure." ;
    dc:creator "['Ko, Ryoung-Eun', 'Na, Soo Jin', 'Huh, Kyungmin', 'Suh, Gee Young', 'Jeon, Kyeongman']" ;
    dc:identifier <http://dx.doi.org/10.1186/s12931-019-1188-6>,
        <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761721>,
        <https://www.ncbi.nlm.nih.gov/pubmed/31554510> ;
    dc:issued "2019-01-01"^^xsd:date ;
    dc:license "CC BY" ;
    dc:title "Association of time-to-treatment with outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients" ;
    sso:has_full_text "True" ;
    sso:journal "Respir Res" ;
    sso:sha "5323d48c2b2aa253087b13694b0e8b0bd0f8ccd7" ;
    sso:source_x "PMC" .

